Sodium hydrosulfide attenuates beta-amyloid-induced cognitive deficits and neuroinflammation via modulation of MAPK/NF-κB pathway in rats

Current Alzheimer Research

Volumn 12, Issue 7, 2015, Pages 673-683

  Liu, Huiyu ^a   Deng, Yuanyuan ^a   Gao, Jianmei ^a   Liu, Yuangui ^a   Li, Wenxian ^a   Shi, Jingshan ^a   Gong, Qihai ^a  

^a ZUNYI MEDICAL UNIVERSITY   (China)

Author keywords

3 mercaptopyruvate sulfurtransferase (3MST); Alzheimer s disease; Beta amyloid1 42; Cystathionine synthase (CBS); Hydrogen sulfide; Neuroinflammation

Indexed keywords

3 MERCAPTOPYRUVATE SULFURTRANSFERASE; AMYLOID BETA PROTEIN; CYCLOOXYGENASE 2; CYSTATHIONINE BETA SYNTHASE; HYDROGEN SULFIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; SODIUM SULFIDE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; AMYLOID BETA-PROTEIN (1-42); NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; PEPTIDE FRAGMENT; SODIUM BISULFIDE; SULFIDE; SULFURTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL COGNITIVE DEFECT; HIPPOCAMPUS; MALE; NERVOUS SYSTEM INFLAMMATION; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RANDOMIZATION; RAT; ALZHEIMER DISEASE; ANIMAL; CELL DEATH; COGNITION DISORDERS; DISEASE MODEL; DRUG EFFECTS; IMMUNOMODULATION; INTRAPERITONEAL DRUG ADMINISTRATION; MAZE TEST; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CELL DEATH; COGNITION DISORDERS; CYSTATHIONINE BETA-SYNTHASE; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; INJECTIONS, INTRAPERITONEAL; MALE; MAP KINASE SIGNALING SYSTEM; MAZE LEARNING; NEUROIMMUNOMODULATION; NEURONS; NEUROPROTECTIVE AGENTS; NF-KAPPA B; NOOTROPIC AGENTS; PEPTIDE FRAGMENTS; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; SULFIDES; SULFURTRANSFERASES;

EID: 84952651343     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666150713102326     Document Type: Conference Paper

References (54)

1. [1] Devi L, Ohno M. Mitochondrial dysfunction and accumulation of the beta-secretase-cleaved c-terminal fragment of app in alzheimer's disease transgenic mice. Neurobiol Dis 45(1): 417-424 (2012).
2. [2] Kawas CH, Corrada MM. Alzheimer's and dementia in the oldestold: A century of challenges. Curr Alzheimer Res 3(5): 411-419 (2006).
3. [3] Zilkens RR, Bruce DG, Duke J, Spilsbury K, Semmens JB. Severe psychiatric disorders in mid-life and risk of dementia in late- life (age 65-84 years): A population based case-control study. Curr Alzheimer Res 11(7): 681-693 (2014).
4. [4] Seabrook TJ, Jiang L, Maier M, Lemere CA. Minocycline affects microglia activation, abeta deposition, and behavior in app-tg mice. Glia 53(7): 776-782 (2006).
5. [5] Gosselet F, Saint-Pol J, Candela P, Fenart L. Amyloid-beta peptides, alzheimer's disease and the blood-brain barrier. Curr Alzheimer Res 10(10): 1015-1033 (2013).
6. [6] Eikelenboom P, Veerhuis R, Familian A, Hoozemans JJ, van Gool WA, Rozemuller AJ. Neuroinflammation in plaque and vascular beta-amyloid disorders: Clinical and therapeutic implications. Neurodegener Dis 5(3-4):190-193(2008).
7. [7] Mrak RE. Neuropathology and the neuroinflammation idea. J Alzheimer's Dis 18(3): 473-481 (2009).
8. [8] Octave JN, Pierrot N. Alzheimer's disease: Cellular and molecular aspects. Bull Acad Natl Med 192(2): 323-331 (2008); discussion 331-322.
9. [9] Wang CM, Liu MY, Wang F, Wei MJ, Wang S, Wu CF, et al. Anti-amnesic effect of pseudoginsenoside-f11 in two mouse models of alzheimer's disease. Pharmacol, Biochem Behav 106: 57-67, (2013).
10. [10] Ji XF, Chi TY, Xu Q, He XL, Zhou XY, Zhang R, et al. Xanthoceraside ameliorates mitochondrial dysfunction contributing to the improvement of learning and memory impairment in mice with intracerebroventricular injection of abeta1-42. Evid-Based Complement Alternat Med 214: 969342 (2014).
11. [11] Liu Z, Zhao X, Liu B, Liu AJ, Li H, Mao X, et al. Jujuboside a, a neuroprotective agent from semen ziziphi spinosae ameliorates behavioral disorders of the dementia mouse model induced by abeta 1-42. Eur J Pharmacol 738: 206-213 (2014).
12. [12] Huang T, Fang F, Chen L, Zhu Y, Zhang J, Chen X, et al. Ginsenoside Rg1 attenuates oligomeric abeta(1-42)-induced mitochondrial dysfunction. Curr Alzheimer Res 9(3): 388-395 (2012).
13. [13] Potter PE: Investigational medications for treatment of patients with alzheimer disease. J Am Osteopathic Assoc 110(9 Suppl 8): 27-36 (2010).
14. [14] Kimura H. Hydrogen sulfide: Its production, release and functions. Amino Acids 41(1): 113-121 (2011).
15. [15] Kimura H. Physiological role of hydrogen sulfide and polysulfide in the central nervous system. Neurochem Intern 63(5): 492-497 (2013).
16. [16] Liu YY, Bian JS. Hydrogen sulfide protects amyloid-beta induced cell toxicity in microglia. J Alzheimer's Dis 22(4):1189-1200 (2010).
17. [17] Zhang Y, Tang ZH, Ren Z, Qu SL, Liu MH, Liu LS, et al. Hydrogen sulfide, the next potent preventive and therapeutic agent in aging and age-associated diseases. Mol Cell Biol 33(6): 1104-1113 (2013).
18. [18] Xuan A, Long D, Li J, Ji W, Zhang M, Hong L, et al. Hydrogen sulfide attenuates spatial memory impairment and hippocampal neuroinflammation in beta-amyloid rat model of alzheimer's disease. J Neuroinflammation 9: 202 (2012).
19. [19] Hu LF, Wong PT, Moore PK, Bian JS. Hydrogen sulfide attenuates lipopolysaccharide-induced inflammation by inhibition of p38 mitogen-activated protein kinase in microglia. J Neurochem 100(4): 1121-1128 (2007).
20. [20] Liu X, Jiang P, Huang H, Yan Y. Plasma levels of endogenous hydrogen sulfide and homocysteine in patients with alzheimer's disease and vascular dementia and the significance thereof. Zhonghua Yi Xue Za Zhi 88(32): 2246-2249 (2008).
21. [21] Kamoun P. Endogenous production of hydrogen sulfide in mammals. Amino acids 26(3): 243-254 (2004).
22. [22] Fan H, Guo Y, Liang X, Yuan Y, Qi X, Wang M, et al. Hydrogen sulfide protects against amyloid beta-peptide induced neuronal injury via attenuating inflammatory responses in a rat model. J Biomed Res 27(4): 296-304 (2013).
23. [23] Gong QH, Pan LL, Liu XH, Wang Q, Huang H, Zhu YZ. Spropargyl- cysteine (zyz-802), a sulphur-containing amino acid, attenuates beta-amyloid-induced cognitive deficits and proinflammatory response: Involvement of erk1/2 and nf-kappab pathway in rats. Amino Acids 40(2): 601-610 (2011).
24. [24] Hu LF, Lu M, Tiong CX, Dawe GS, Hu G, Bian JS. Neuroprotective effects of hydrogen sulfide on parkinson's disease rat models. Aging Cell 9(2): 135-146 (2010).
25. [25] Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Meth 11(1): 47-60 (1984).
26. [26] Biagini G, D'Arcangelo G, Baldelli E, D'Antuono M, Tancredi V, Avoli M. Impaired activation of ca3 pyramidal neurons in the epileptic hippocampus. Neuromol Med 7(4): 325-342 (2005).
27. [27] Gong QH, Wang Q, Pan LL, Liu XH, Xin H, Zhu YZ. S-propargylcysteine, a novel hydrogen sulfide-modulated agent, attenuates lipopolysaccharide-induced spatial learning and memory impairment: Involvement of tnf signaling and nf-kappab pathway in rats. Brain Behav Immun 25(1): 110-119 (2011).
28. [28] Wang S, Liu Z, Wang L, Zhang X. Nf-kappab signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol 6(5): 327-334 (2009).
29. [29] He XL, Yan N, Zhang H, Qi YW, Zhu LJ, Liu MJ, et al. Hydrogen sulfide improves spatial memory impairment and decreases production of abeta in app/ps1 transgenic mice. Neurochem Intern 67(1-8) (2014).
30. [30] Shibuya N, Tanaka M, Yoshida M, Ogasawara Y, Togawa T, Ishii K, et al. 3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain. Antioxid Redox Signal 11(4):703-714 (2009).
31. [31] Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci 16(3): 1066-1071 (1996).
32. [32] Morrison LD, Smith DD, Kish SJ. Brain s-adenosylmethionine levels are severely decreased in alzheimer's disease. J Neurochem 67(3): 1328-1331 (1996).
33. [33] Li MH, Tang JP, Zhang P, Li X, Wang CY, Wei HJ, et al. Disturbance of endogenous hydrogen sulfide generation and endoplasmic reticulum stress in hippocampus are involved in homocysteine-induced defect in learning and memory of rats. Behav Brain Res 262: 35-41 (2014).
34. [34] Kimura H, Shibuya N, Kimura Y. Hydrogen sulfide is a signaling molecule and a cytoprotectant. Antioxid Redox Signal 17(1): 45-57 (2012).
35. [35] Rosi S, Ramirez-Amaya V, Vazdarjanova A, Worley PF, Barnes CA, Wenk GL. Neuroinflammation alters the hippocampal pattern of behaviorally induced arc expression. J Neurosci 25(3):723-731 (2005).
36. [36] Tanaka S, Ide M, Shibutani T, Ohtaki H, Numazawa S, Shioda S, Yoshida T. Lipopolysaccharide-induced microglial activation induces learning and memory deficits without neuronal cell deathin rats. J Neurosci Res 83(4): 557-566 (2006).
37. [37] Morales I, Farias G, Maccioni RB. Neuroimmunomodulation in the pathogenesis of alzheimer’s disease. Neuroimmunomodulation 17(3): 202-204 (2010).
38. [38] Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of alzheimer's disease. J Neurosci 25(39): 8843-8853 (2005).
39. [39] Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar β-amyloid and iggs are differentially regulated by proinflammatory cytokines. J Neurosci (2005) 25(36): 8240-8249.
40. [40] Angelopoulos P, Agouridaki H, Vaiopoulos H, Siskou E, Doutsou K, Costa V, et al. Cytokines in alzheimer's disease and vascular dementia. Intern J Neurosci 118(12): 1659-1672 (2008).
41. [41] Forlenza OV, Diniz BS, Talib LL, Mendonca VA, Ojopi EB, Gattaz WF, et al. Increased serum il-1beta level in alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn Disord 28(6): 507-512 (2009).
42. [42] Cheng G, Whitehead SN, Hachinski V, Cechetto DF. Effects of pyrrolidine dithiocarbamate on beta-amyloid (25-35)-induced inflammatory responses and memory deficits in the rat. Neurobiol Dis 23(1): 140-151 (2006).
43. [43] Wan F, Lenardo MJ. The nuclear signaling of nf-kappab: Current knowledge, new insights, and future perspectives. Cell Res 20(1): 24-33 (2010).
44. [44] Baeuerle PA, Henkel T. Function and activation of nf-kappab in the immune system. Ann Rev Immunol 12(1): 141-179 (1994).
45. [45] Kim EK, Choi EJ. Pathological roles of mapk signaling pathways in human diseases. Biochim Biophys Acta 1802(4): 396-405 (2010).
46. [46] Webster B, Hansen L, Adame A, Crews L, Torrance M, Thal L, et al. Astroglial activation of extracellular-regulated kinase in early stages of alzheimer disease. J Neuropathol Exp Neurol 65(2): 142-151 (2006).
47. [47] Arancio O, Zhang HP, Chen X, Lin C, Trinchese F, Puzzo D, et al. Rage potentiates abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 23(20): 4096-4105 (2004).
48. [48] Chong YH, Shin YJ, Lee EO, Kayed R, Glabe CG, Tenner AJ. Erk1/2 activation mediates abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem 281(29): 20315-20325.
49. [49] Rapoport M, Ferreira A. Pd98059 prevents neurite degeneration induced by fibrillar beta-amyloid in mature hippocampal neurons. J Neurochem 74(1): 125-133 (2000).
50. [50] Franciosi S, Ryu JK, Choi HB, Radov L, Kim SU, McLarnon JG. Broad-spectrum effects of 4-aminopyridine to modulate amyloid β1–42-induced cell signaling and functional responses in human microglia. J Neurosci 26(45): 11652-11664 (2006).
51. [51] Culbert AA, Skaper SD, Howlett DR, Evans NA, Facci L, Soden PE, et al. Mapk-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of alzheimer disease. J Biol Chem 281(33): 23658-23667 (2006).
52. [52] Wei W, Norton DD, Wang X, Kusiak JW. Abeta 17-42 in alzheimer's disease activates jnk and caspase-8 leading to neuronal apoptosis. Brain 125(9): 2036-2043 (2002).
53. [53] Munoz L, Ranaivo HR, Roy SM, Hu W, Craft JM, McNamara LK, et al. A novel p38α mapk inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an alzheimer's disease mouse model. J Neuroinflammation 4(1): 21 (2007).
54. [54] Austrom MG, Lu Y: Long term caregiving: Helping families of persons with mild cognitive impairment cope. Curr Alzheimer Res 6(4): 392-398 (2009).